Highlights

  • Third quarter net loss was USD 617,651 against USD 666,737 a year earlier.
  • Nine-month net loss was USD 2,157,341 against USD 2,424,348.
  • Research and development expense was USD 242,569 against USD 187,808.
  • Accumulated losses since inception were approximately USD 90.3 million.

Bone Biologics Corp (NASDAQ:BBLG) shares were trading near their all-time low at USD 0.3272 on November 6, 2026, up 1.08% on the day. The medical device company reported a third quarter net loss of USD 617,651, or USD 0.17 per share.

Bone Biologics focuses on bone regeneration in spinal fusion using NELL-1, a recombinant human protein used with demineralized bone matrix. The filing describes the combination as an osteopromotive product that provides target specific control over bone regeneration.

Third Quarter and Nine-Month Results

Total operating expenses were USD 666,340 against USD 715,274 in the third quarter of 2025. The loss from operations equaled those amounts. The net loss was USD 617,651 against USD 666,737, and the loss per share was USD 0.17 against USD 0.37.

For the nine months ended September 30, 2026, total operating expenses were USD 2,279,501 against USD 2,501,837. The net loss was USD 2,157,341 against USD 2,424,348, or USD 0.88 per share against USD 2.51 per share. Weighted average shares were 3,737,327 in the quarter against 1,795,097.

Expense Detail

Research and development expense was USD 242,569 against USD 187,808, an increase of USD 54,761. The filing ties the increase to development activities to extend the shelf-life of the protein.

General and administrative expense decreased by USD 103,695 to USD 423,771 from USD 527,466. The filing describes the timing of director compensation expense recognition, which follows the annual meeting.

Balance Sheet and Cash Flow

Total Assets were USD 6,432,445 at September 30, 2026 against USD 5,796,135 at December 31, 2025. Total liabilities were USD 480,775 against USD 418,587, and total stockholders' Equity was USD 5,951,670 against USD 5,377,548.

The accumulated Deficit was USD 90,287,710. Net cash used in Operating Activities was USD 1,854,997 for the nine months against USD 1,976,388.

Outlook for Spending

The filing states that the company has no significant operating history and will continue to incur significant expenses for development of its lead product, NELL-1 with demineralized bone matrix. Share and per share amounts have been restated for the Reverse Stock Split as if it occurred at the start of the earliest period presented.

The company had 3,389,057 shares of common stock outstanding as of October 26, 2026.

Cash and Financing

The filing states that the company had cash of USD 6.1 million at September 30, 2026, against cash of USD 5,334,322 at the start of the year. Cash at the end of the nine-month period was USD 6,088,085 against USD 6,049,084 a year earlier.

Net cash provided by financing activities was USD 2,608,760 for the nine months against USD 4,700,341 in the same period of 2025. The company's ability to raise additional Capital is subject to certain conditions described in its notes. On June 5, 2025, it filed an amendment to its certificate of incorporation, which the notes tie to its reverse stock split.